Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

WuXi Breaks Ground on New Cell Therapy Manufacturing Facility

Published: Thursday, May 01, 2014
Last Updated: Thursday, May 01, 2014
Bookmark and Share
The facility in Philadelphia is expected to become operational in the second quarter of 2015.

The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility. This expansion will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. The new facility will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.

Located in the Philadelphia Navy Yard, the new facility will complement WuXi's existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in Philadelphia.

"Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster," said Dr.Ge Li, Chairman and CEO of PharmaTech.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China
Company will provide full-service clinical trial services for global clinical trials subcontracted by PRA in China.
Tuesday, December 15, 2015
WuXi PharmaTech and Lilly Announce Strategic Collaboration
Collaboration to develop, manufacture and commercialize a novel small molecule in China.
Saturday, November 14, 2015
WuXi, Lilly Announce Strategic Collaboration
WuXi PharmaTech and Eli Lilly have announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.
Thursday, November 12, 2015
WuXi PharmaTech Receives First Approval from Japanese Regulatory Authorities
STA subsidiary receives approval for the manufacture of the GMP intermediate of a branded commercial drug.
Thursday, September 03, 2015
WuXi PharmaTech and TruTag Complete Successful Testing of Authentication Solution
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics.
Thursday, August 20, 2015
WuXi and TruTag Complete Successful Testing of Edible On-Dose Authentication Solution for Pharmaceuticals
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics.
Wednesday, August 12, 2015
WuXi PharmaTech to Build New Cell Therapy Manufacturing Facility
Facility is designed for CAR T cells and other cancer immunotherapies.
Friday, March 20, 2015
WuXi Acquires NextCODE Health
NextCODE and WuXi's Genome Center will offer comprehensive clinical, research, and diagnostic testing products and services worldwide.
Monday, January 12, 2015
WuXi Opening Offices in Boston and San Francisco
New offices will give access to innovative companies in the world's two leading biotech hubs.
Friday, December 19, 2014
WuXi PharmaTech Laboratory Testing Division Expands in U.S.
XenoBiotic acquisition expands LTD’s presence in North America.
Wednesday, October 08, 2014
WuXi Facility Passes FDA API Manufacture Inspection
Company's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) passed an FDA inspection in July for the manufacture of the active pharmaceutical ingredient (API) for a branded commercial drug.
Wednesday, August 20, 2014
WuXi PharmaTech Begins Operation of New HPAPI Laboratory
Adds HPAPI processing capabilities at Shanghai lab.
Thursday, May 29, 2014
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility
Company announces that construction has been completed on a new biologics biosafety testing facility in Suzhou.
Tuesday, May 13, 2014
WuXi PharmaTech Announces Management Appointments
Dr. Steve Yang joins Company as EVP and chief operating officer and Edward Hu named chief investment officer and remains chief financial officer.
Thursday, April 17, 2014
WuXi and PRA Form Joint Venture
The agreement will offer a broad platform of Phase I-IV clinical trial services in China, Hong Kong and Macau.
Tuesday, January 01, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!